Azushima Kengo, Tamura Kouichi, Haku Sona, Wakui Hiromichi, Kanaoka Tomohiko, Ohsawa Masato, Uneda Kazushi, Kobayashi Ryu, Ohki Kohji, Dejima Toru, Maeda Akinobu, Hashimoto Tatsuo, Oshikawa Jin, Kobayashi Yusuke, Nomura Koichiro, Azushima Chieko, Takeshita Yasuyo, Fujino Ryota, Uchida Ken, Shibuya Ken, Ando Daisaku, Tokita Yasuo, Fujikawa Tetsuya, Toya Yoshiyuki, Umemura Satoshi
Department of Medical Science and Cardiorenal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
Department of Medical Science and Cardiorenal Medicine, Yokohama City University, Graduate School of Medicine, Yokohama, Japan.
Atherosclerosis. 2015 May;240(1):297-304. doi: 10.1016/j.atherosclerosis.2015.01.025. Epub 2015 Mar 25.
OBJECTIVE: There is no clinical evidence that supports the benefit of integrative medicine, defined as combination therapy of oriental and western medicine, on obesity-related hypertension. This study evaluates the efficacy of Bofu-tsusho-san (BOF), an oriental herbal medicine, on the ambulatory blood pressure (BP) profile in hypertensive patients with obesity. METHODS: The study design was a multicenter, randomized, open-label, parallel-group controlled trial in 107 hypertensive patients with obesity. Participants were randomly assigned to receive either the conventional control therapy or BOF add-on therapy. In both groups antihypertensive therapy was aimed at achieving the target clinic BP. The primary outcome was change in the ambulatory BP profile from baseline to 24 weeks after randomization. RESULTS: Daytime systolic BP variability, an important parameter of ambulatory BP profile, was decreased in the BOF group, and the difference in the changes in daytime systolic BP variability was significant between the BOF and control group (Control vs BOF; the change from baseline in daytime systolic BP variability, 1.0±3.3 vs -1.0±3.3%; p=0.006). CONCLUSION: The BOF add-on therapy effectively improved the ambulatory BP variability. This is the first report suggesting that an integrative medicine approach may exert favorable effects on obesity-related hypertension compared with conventional pharmaceutical treatment. CLINICAL TRIAL REGISTRATION: UMIN000003878.
Zhonghua Liu Xing Bing Xue Za Zhi. 2004-8
Front Pharmacol. 2023-5-18
J Clin Hypertens (Greenwich). 2023-5
BMC Complement Med Ther. 2023-4-12